- Home
- CSTL
as 10-07-2025 3:30pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 697.9M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 348.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.59 - $35.84 | Next Earning Date: | 11-03-2025 |
| Revenue: | $346,269,000 | Revenue Growth: | 20.40% |
| Revenue Growth (this year): | -2.44% | Revenue Growth (next year): | -1.26% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Oct 2 '25 | Sell | $22.58 | 1,339 | $30,234.62 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Sep 17 '25 | Sell | $21.97 | 1,339 | $29,419.17 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Sep 2 '25 | Sell | $23.93 | 1,339 | $32,042.27 | 64,327 | |
| Oelschlager Kristen M | CSTL | Chief Operating Officer | Aug 27 '25 | Sell | $21.85 | 30,684 | $669,706.69 | 153,793 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Aug 15 '25 | Sell | $20.04 | 1,339 | $26,833.56 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Aug 13 '25 | Sell | $19.50 | 43,019 | $839,042.58 | 64,327 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
GlobeNewswire
4 months ago
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 months ago
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions
GlobeNewswire
4 months ago
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
GlobeNewswire
4 months ago
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
GlobeNewswire
4 months ago
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
GOBankingRates
4 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
4 months ago
3 International Vacations That Are Cheaper Than an iPhone
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.